Follow-up Abstract/Off Study Form (Form 82)

Subject ID# (preprinted) Visit #: 4

- If the subject is active in the study, supply information at the time of the MHCS-II Follow-up visit.
- If the subject is <u>no longer active in the study</u> for any reason, supply information through last clinic visit.

Subject Verification Info:			Date of 2 nd Follow-up visit (preprinted); DOB (preprinted); Sex (preprinted)					
1.	Subject's status		 □ currently active in study→ GO TO 3 □ deceased→ GO TO 1a □ transferred to another clinic→ GO TO 2 Clinic/City: □ withdrew from study→ GO TO 2 					
			Check primary reason.	 Too ill to pa Already inv No longer i Genetic test Confidentia 	volved in another nterested ting concerns	study		
	1a.	Date of death:	- - _ Month Day		_			
	Other HIV D Liver Failure Hemorrhage, Other Blood Lymphoma Cancer: Trauma Heart Diseas Renal Diseas		Bleeding Disorder e e elated Infections y:	(Cł	Primary Cause Second (Check only one) (Check DS Diagnosis			
			performed?	🗖 Yes	🗖 No	🗖 Unknown		
	1d.	Was liver tissue of	obtained?	□ Yes	🗖 No	Unknown		
	1e.	Source of death i Check all that ap		 Death c Medica Spouse Non-rel Obituar Other: 	l record or relative lative			

2.	Date c visit.	of the subject's most recent clinic	 Month	
	2a.	<u>After</u> date of 2^{nd} Follow-up visit <u>Same as</u> date of 2^{nd} Follow-up visit		GO TO 4 GO TO END
3.	Date of	f MHCS-II Follow-up visit.	 Month	 Day Year
4.	From c	lata previously submitted to MHCS-II, th	e subjec	t's hemophilia genetic defect is:
		RTED: (preprinted) currently accurate?		Yes \rightarrow GO TO 5 No \rightarrow GO TO 4a
5.	blood of since: (Date of <i>IF <u>ON</u></i>	e <u>all</u> clotting factor products and components the subject has used of 2 nd Follow-up visit-preprinted) <u>LY</u> 'OTHER BLOOD PONENTS', GO TO 8		None \rightarrow GO TO 8 Recombinant Monoclonal High Purity Intermediate Purity Cryoprecipitate Other blood components (include whole blood, platelets, red cells, plasma)
6.		ximately how much factor concentrate subject receive since the 2 nd Follow-up		None → <i>GO TO 7</i> FVIII/FIX Units: FVIIa Micrograms: Unknown
	6a.	On what basis was the factor administered?		Both prophylactically and on demand Only on demand (for a bleed)

7.	Approximately how many units of cryoprecipitate did the subject receive since the 2 nd Follow-up visit? (If available, record total mls; if not, record # of bags)		None Total mls: OR # of bags: Unknown
8.	Since the 2 nd Follow-up visit, did the subject receive an HBV vaccine?		Yes No Unknown
9.	From data previously submitted to MHCS-II, t REPORTED:	he subje	ct's HBV status is determined to be:
	Is this currently accurate?		Yes \rightarrow GO TO 10 No \rightarrow GO TO 9a
10.	Since the 2 nd Follow-up visit has the subject been vaccinated for hepatitis A?		Yes \rightarrow _ Month / Year of last vaccination
	been vaccinated for nepatitis A?		No Unknown
11.	What is the subject's current HCV antibody status? If no test in the past 12 months, record 'unknown'.		Positive Negative Unknown
11.	What is the subject's HIV status?		Positive Negative \rightarrow GO TO 14

13. Since the 2^{ndt} Follow-up visit, was the subject newly diagnosed with any of the AIDS-defining conditions?


Yes No → *GO TO 14*

13a. Indicate AIDS-defining illness(es) and the date it was first diagnosed. *Bolded items are cancers to report at Q. 22.*

	Month	and Y	ear		Month and Year
CD4 <200 cells/µL or <14%				Mycobacterium avium (not only	
CMV (not liver, spleen, lymph)		- _		lungs, skin, cervical nodes)	
Candidiasis of esophagus or lungs		- _		Non-Hodgkin's Lymphoma	
Cervical cancer, invasive		-		(not T-cell or CNS Primary)	-
Coccidioidmycosis, extrapulmonary				Pneumocystis carinii pneumonia	
Cryptococcosis, extrapulmonary		-		(PCP)	
Cryptosporidiosis with diarrhea				Pneumonia, recurrent bacterial	
for > 1 month	_	_ -		(more than once in 12 months)	-
Herpes simplex, ulcer for > 1 month	_	_ -		Progressive multifocal	
Herpes simplex in lungs or esophagu	ıs _	_ -		leukoencephalopathy (PML)	-
Histoplasmosis, extrapulmonary	_	_ -		Pulmonary tuberculosis	-
HIV encephalopathy/dementia	_	_ -		Salmonella septicemia, recurrent	-
Isosporiasis with diarrhea				Toxoplasmosis of the brain	-
for > 1 month	_	_ -		Wasting syndrome	
Kaposi's Sarcoma	_	_ -		(emaciation, "slim disease")	-
Lymphoid interstitial pneumonia (Ll	P)			Other multiple or recurrent	
or pulmonary lymphoid hyperplasia		_ -		bacterial infections at least 2 in	
Lymphoma of the brain				a 2-year period	_ - _
(CNS Primary)		_ -			

- 14. Since the 2nd Follow-up visit, has the subject been diagnosed with any of the following HCV-related conditions? For each one the subject has had, record the date of diagnosis. If the subject has not been diagnosed with any of these, choose 'NONE'. *Bolded items are cancers to report at Q. 22.*
 - □ NONE
 - \Box Jaundice, persistent > 1 month
 - □ Ascites (hepatic-related)
 - □ Hepatic encephalopathy
 - **D** Esophageal varices
 - **D** Bleeding esophageal varices
 - **Hepatocellular carcinoma (hepatoma)**
 - □ Mixed (Type II) cryoglobulinemia
 - □ Aplastic anemia
 - **D** Porphyria cutanea tarda
 - □ Membranoproliferative glomerulonephritis
 - □ Biopsy proven Cirrhosis
 - Other:

Month and year



We'd like to know about treatments the subject received for HCV since the 2nd Follow-up visit. Some brand names of HCV drugs are:

	urugs urv	•Standard interferon alone = <i>Intron</i> •Ribavirin = <i>Rebetol, Virazole, Cop</i> •Standard interferon + ribavirin tog •Pegylated interferon = <i>PEG-Introp</i>	<i>pegus</i> gether in o	one medication = <i>Rebetron</i>
15.		the subject receive any treatment for since the 2^{nd} Follow-up visit?		Yes No → GO TO 20
16.		he subject treated at the same time tandard interferon and ribavirin?		Yes No → <i>GO TO 17</i>
	16a.	What brand was used? If 2 <u>separate</u> drugs used, indicate brand of <u>both</u> drugs. If don't know, write "DK" on line.		Rebetron (standard interferon and ribavirin combined) Other standard inteferon: Other ribavirin:
	16b.	When did use begin?	 Month	_ - Year
	16c.	Is the subject currently using it?		Yes→ GO TO 17 No
	16d.	Why is the subject no longer using it?		Stopped use early because of side effects. Stopped use early because HCV failed to clear Completed prescribed treatment
17.		ne subject treated with <i>standard</i> eron <u>without</u> ribavirin?		Yes No → <i>GO TO 18</i>
	17a.	What brand was used? If don't know, write "DK" on line.		Intron Roferon Infergen Other standard interferon:
	17b.	When did use begin?	 Month	_ - Year
	17c.	Is the subject currently using it?		Yes→ GO TO 18 No
	17d.	Why is the subject no longer using it?		Stopped use early because of side effects Stopped use early because HCV failed to clear Completed prescribed treatment

18.		he subject treated at the same time begylated interferon and ribavirin?		Yes No → <i>GO TO 19</i>
	18a.	What brand was used? Indicate brands of both drugs. If don't know, write "DK" on line.		PEG-Intron (pegylated interferon brand name) Pegasys (pegylated interferon brand name) Rebetol (ribavirin brand name) Virazole (ribavirin brand name) Other pegylated interferon: Other ribavirin:
	18b.	When did use begin?	 Month	_ - Year
	18c.	Is the subject currently using it?		Yes→ <i>GO TO 19</i> No
	18d.	Why is the subject no longer using it?		Stopped use early because of side effects Stopped use early because HCV failed to clear Completed prescribed treatment
19.		he subject treated with <i>pegylated</i> eron <u>without</u> ribavirin?		Yes No → <i>GO TO 20</i>
	19a.	What brand was used? <i>If don't know, write "DK" on line.</i>		PEG-Intron (pegylated interferon brand name) Pegasys (pegylated interferon brand name) Other pegylated interferon:
	19b.	When did use begin?	 Month	_ - Year
	19c.	Is the subject currently using it?		Yes→ GO TO 20 No
	19d.	Why is the subject no longer using it?		Stopped use early because of side effects. Stopped use early because HCV failed to clear Completed prescribed treatment
20.		the 2 nd Follow-up visit, has the et had a <u>liver biopsy</u> ?		Yes \rightarrow SEND PATH REPORT(S) AND SPECIMEN No \rightarrow GO TO 21
	20a.	What was the reason for the biopsy?		Clinical decision making Eligibility for clinical trial Other:

21. Since the 2^{nd} Follow-up visit, has the				Yes, formally evaluated by a transplant team $\rightarrow GO$	
	subject been considered for or evaluated for a liver transplant?			<i>TO 21a</i> Yes, considered but not formally evaluated by a	
				transplant team $\rightarrow GO \ TO \ 22$ No, not considered or evaluated $\rightarrow GO \ TO \ 22$	
	21a. Has the subject received a liver transplant?			Unknown $\rightarrow GO TO 22$	
				Yes $\rightarrow \ $ - $ \ $ - $ \ $ Month Year of transplant	
				No, but on the eligibility list No, not currently on eligibility list	
22.		he 2 nd Follow-up visit, has the subject		Yes → SEND PATH REPORT(S)	
	been diagnosed with any type of cancer? Be sure to include those cancers you listed at 13a and 14.			$AND SPECIMEN$ No $\rightarrow GO TO 23$	
Cancer	r#1 ;	a. Primary site			
	1	о. Туре	Hist	ologic subtype	
	(e. Is this cancer localized to the		Localized	
		primary site or metastatic?		Metastatic	
	d. Diagnosis date		- Month Year		
Cancer	r#2 a	a. Primary site			
	1	р. Туре	Hist	ologic subtype	
		. Is this cancer localized to the		Localized	
		primary site or metastatic?		Metastatic	
		d. Diagnosis date	 Mor	- .th Year	

23.	Has the subject had an upper GI bleed, gastrointestinal perforation or gastrointestinal obstruction (stenosis) <u>since the 2nd Follow-up</u> visit? (Check all that apply. If uncertain whether GI bleed is upper, check yes and complete the supplement.)		NO→GO TO 24 Yes, upper GI bleed Yes, gastrointestinal perforation Yes, gastrointestinal obstruction (stenosis)
	23a. Have you sent in an Upper GI Supplement Form?		Yes No → <i>COMPLETE THE UPPER GI</i> SUPPLEMENT FOR THIS SUBJECT.
	23b.Date the bleed occurred	 Month	
24.	Date this form completed	 Month	_ - _ - Day Year